Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

Nurse practitioners form the key to providing culturally competent care, which improves outcomes for Asian American patients.

Several medical organizations are suing the HHS and Secretary Robert F. Kennedy Jr based on recent actions resulting in significant changes in vaccine policy in the US.

The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.

The prevalence of long COVID-typical symptom clusters was relatively high among a cohort of adults 2 years after initial COVID-19 infection.

The Trump administration's recent travel and visa restrictions have left some hospitals in the United States without essential staff.

The US FDA has published more than 200 complete response letters sent as replies to drug and biological product applications.

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a recent CDC update.

Children with hematologic malignancies continue to exhibit increased IPD risk despite an overall decline in pediatric IPD after the introduction of the PCV13 vaccine.

Incomplete immune recovery despite sustained virologic suppression in patients with HIV was associated with increased risk for incident cancer.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.